{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-26-012287","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2026-08-13T13:14:34+00:00","discovered_at":"2026-08-13T13:16:04.274612+00:00","generated_at":"2026-08-13T13:16:09.883561+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ADC Therapeutics Q2 revenue $18.6M; FDA flags LOTIS-5 benefit-risk concerns","bullets":["Q2 net product revenue $18.6M vs $18.1M YoY; six-month revenue $38.7M vs $35.5M.","Q2 net loss $16.6M ($0.11/share) vs $56.6M loss in 2025; adjusted net loss $16.3M.","Cash $219.1M at June 30, 2026; runway at least into 2028.","FDA pre-sBLA meeting cited Grade 5 event imbalance and marginal benefit; regulatory path under review.","17% workforce cut yields ~$10M annual savings; LOTIS-7 enrollment complete at 100 patients."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-26-012287","json":"https://secwatch.observer/filing/0000950103-26-012287.json","markdown":"https://secwatch.observer/filing/0000950103-26-012287.md","text":"https://secwatch.observer/filing/0000950103-26-012287.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326012287/0000950103-26-012287-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000095010326012287/dp251718_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T13:16:09.883561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}